AI Unleashed: Featuring Experts from Poolbeg Pharma & CytoReason

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of the adoption

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a declining cancer

Reducing cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma promising results for POLB 001 in cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced CRS. Key highlights –     

Key AI trends in Drug Discovery

2023 was the year of AI. It would be difficult to finish your day without seeing or hearing at least 5 updates about developments related to AI, ChatGPT or language models. The year was marked by significant strides

DirectorsTalk

Companies to follow in 2024

Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas and mining

5 ways pharma can safely leverage AI for drug discovery

In recent years, those applying computer science to biology have had no trouble raising the money to take their innovations straight into the commercial world. The promise was simple: get your hands on large datasets and machine learning

Poolbeg Pharma: Year in Review 2023

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg identifies strategic drug targets for treatment of RSV

Biopharmaceutical company Poolbeg has selected as strategic priority a number of potential treatments for Respiratory Syncytial Virus. The drug targets were selected from a list identified as part of Poolbeg’s artificial intelligence-led programme, which identified the potential treatments

No more posts to show